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Abstract
The gastric-derived orexigenic peptide ghrelin affects brain circuits involved in energy balance as well as in reward. Indeed,
ghrelin activates an important reward circuit involved in natural- as well as drug-induced reward, the cholinergic-
dopaminergic reward link. It has been hypothesized that there is a common reward mechanism for alcohol and sweet
substances in both animals and humans. Alcohol dependent individuals have higher craving for sweets than do healthy
controls and the hedonic response to sweet taste may, at least in part, depend on genetic factors. Rat selectively bred for
high sucrose intake have higher alcohol consumption than non-sucrose preferring rats and vice versa. In the present study a
group of alcohol-consuming individuals selected from a population cohort was investigated for genetic variants of the
ghrelin signalling system in relation to both their alcohol and sucrose consumption. Moreover, the effects of GHS-R1A
antagonism on voluntary sucrose- intake and operant self-administration, as well as saccharin intake were investigated in
preclinical studies using rodents. The effects of peripheral grelin administration on sucrose intake were also examined. Here
we found associations with the ghrelin gene haplotypes and increased sucrose consumption, and a trend for the same
association was seen in the high alcohol consumers. The preclinical data show that a GHS-R1A antagonist reduces the intake
and self-administration of sucrose in rats as well as saccharin intake in mice. Further, ghrelin increases the intake of sucrose
in rats. Collectively, our data provide a clear indication that the GHS-R1A antagonists reduces and ghrelin increases the
intake of rewarding substances and hence, the central ghrelin signalling system provides a novel target for the
development of drug strategies to treat addictive behaviours.
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Introduction
Human imaging studies reveal an underlying disruption in the
reward systems in addictive behaviors including alcohol use
disorder and binge eating [1,2,3] and common neurobiological
mechanisms may underlie these diseases. Recently, ghrelin and its
receptor (GHS-R1A) have been implied for such roles [4,5,6]. The
gastric-derived orexigenic peptide, ghrelin [7], affects brain
circuits involved in energy balance [8] as well as in reward
[9,10]. Indeed, ghrelin activates an important reward circuit
involved in natural- as well as drug-induced reward, the
cholinergic-dopaminergic reward link [11,12]. This reward link
encompasses a dopaminergic projection from the ventral tegmen-
tal area (VTA) to the nucleus accumbens (N.Acc.) that forms part
of the mesolimbic dopamine system, together with a cholinergic
projection from the laterodorsal tegmental area (LDTg) to the
VTA. Ghrelin may, via activation of this reward link, increase the
incentive value of motivated behaviors such as food and drug
seeking [10]. Supportively, alcohol-, cocaine- as well as amphet-
amine-induced reward, as measured by locomotor activity,
accumbal dopamine release and conditioned place preference,
are suppressed by ghrelin receptor (GHS-R1A) antagonism [5,13].
Further, genetic, pharmacologic and surgical rodent models of
altered ghrelin signalling has been used to show that ghrelin action
at the level of the VTA is important for the intake of and
motivation to obtain palatable/rewarding food [6].
The hypothesis of a common reward mechanism for alcohol
and sweet substances also transfers to humans. Interestingly,
alcohol dependent individuals have higher craving for sweets than
do healthy controls [14]. The hedonic response to sweet taste may,
at least in part, depend on genetic factors [15] which have been
shown in both humans and animals in numerous studies
[16,17,18,19,20], and is modulated via several mechanisms, which
include the mesolimbic dopamine system. Specifically, sweet
tasting substances (both caloric and non-caloric) increases the
firing of accumbal dopamine [21].
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sucrose and alcohol into humans, a group of alcohol-consuming
individuals selected from a population cohort was investigated for
genetic variants of the ghrelin signalling system in relation to both
their alcohol and sucrose consumption. Moreover, the effects of
GHS-R1A antagonism on voluntary sucrose- intake and operant
self-administration, as well as saccharin intake were investigated in
preclinical studies using rodents. To exclude the possibility of taste
aversion by the GHS-R1A antagonist, such experiments were
conducted in mice. Additionally, the role of peripheral ghrelin
administration on sucrose consumption in fed rats was examined.
Materials and Methods
Ethics statement
All human subjects gave their written informed consent to the
study, and the protocol was approved by the local ethics
committee in Gothenburg, Forskningsetikkommitte ´O ¨ (ethics
number O ¨ 237-00). This study was performed according to the
tenets of the Helsinki Declaration.
The experiments with mice were approved by the Ethics
Committee for Animal Experiments in Gothenburg, Sweden, and
the experiments with Long Evan rats were pre-approved by the
Gallo Center Institutional Animal Care and Use Committee and
were in accordance with NIH guidelines for the Humane Care
and Use of Laboratory Animals (ethics number 80-07 and
09.02.191).
The population cohort INTERGENE
The individuals of the human genetic study were selected from
the population cohort INTERGENE. INTERGENE is a
population based research program that assesses the INTERplay
between GENEtic susceptibility and environmental factors for the
risk of chronic diseases in western Sweden. The study procedure is
described in detail elsewhere [22,23,24] and at http://www.
intergene.gu.se. In the main questionnaire the participants were,
among other things, asked about the frequency of intake of
different types of alcoholic beverages (low alcohol beer, medium-
strong beer, strong beer, wine, dessert wine and spirits) as well as
on intake of high-sugar containing food. The data on frequencies
and standardized portions of alcoholic beverage consumed per
occasion were used to calculate the total consumption of pure
alcohol in g/day. For the purpose of the present study low-
(n=296) and high (n=283) alcohol consuming individuals were
selected from the total cohort on the basis of their alcohol
consumption (0.3–1.7 g and 20–196 g EtOH/day, respectively).
For all these individuals, the total sucrose intake (g sucrose/day)
was calculated from the section of the above mentioned
questionnaire regarding eating habits including consumption of
sweets (e.g. candy, marmalade, jam, cookies, cake and juice).
Blood samples for genetic analyses were collected from all
individuals. The study sample is more thoroughly described in
Table 1.
Genotyping and genetic association study statistics
All individuals were genotyped for 6 tag SNPs in the pro-ghrelin
gene (GHRL; rs4684677, rs42451, rs35680, rs34911341, rs696217,
rs26802) and 4 tag SNPs of the ghrelin receptor gene (GHSR,
rs2948694, rs572169, rs2232165, rs495225). Genotyping was
performed using TaqMan Pre-Designed SNP Genotyping AssaysH
(Applied Biosystems, Foster City, CA, USA) on the ABI PRISM
7900HT Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) using the TaqMan Allelic Discrimination
technology [25]. The tag SNPs used are the same as in our
previous studies on the ghrelin system and alcohol dependence
[26,27].
Deviation from Hardy Weinberg equilibrium (HWE) for alleles
at individual loci was tested. Differences in clinical characteristics
between groups were analyzed by use of Chi
2-test for categorical
variables, and Mann-Whitney U-test for continuous variables.
Identification of significant covariates for each outcome variable
was made using forward stepwise regression models. Single marker
associations were performed using regression models including
relevant covariates in an additive model (dd=0, Dd=1 and
DD=2, where D=minor allele and d=major allele). Haplotype
analysis was used to identify the haplotype window with strongest
association using forward stepwise logistic or linear haplotype
regression (cut-off p=0.01) always keeping the identified covar-
iates in the model. To this end, haplotype frequencies were
estimated using the expectation-maximization algorithm [28]
yielding all possible haplotypes present in our study population.
In subsequent analyses, however, only haplotypes with an overall
estimated frequency of .5.0% were included, while the rarer
haplotypes were pooled. The p-value threshold for statistical
significance used in this study was p=0.05. To correct for multiple
testing, Bonferroni correction for the number of studied SNPs
(n=10) was used in the single marker analysis and permutation
(10 000 permutations) was used in the sliding window analyses.
The corrected p-values are designated pc. The softwares used for
the statistical analyses were SYSTAT11 (SYSTAT Software
GmbH, Erkrath, Germany) and HelixTree 6.3 (Golden Helix,
Bozeman, MT, USA).
Animals
Both mice and rats were used for the preclinical experiments.
C57BL/6 mice (23–36 g body weight; B&K Universal AB,
Sollentuna, Sweden) were used for the saccharin intake and taste
aversion experiments. This strain was used since it has been used
extensively in the laboratory [5,29,30]. Long–Evans rats (Harlan,
Indianapolis, IN, USA), were used for the intermittent access 20%
sucrose two-bottle-choice drinking paradigm, operant sucrose self-
administration procedures as well as the 5% sucrose two-bottle-
choice drinking paradigm, since such studies are well-documented
in this strain [31,32,33]. All animals were given time to acclimatize
to the individual housing conditions and handling before the start
of the experiments. They were individually housed in ventilated








Age (years) 55 (13) 57 (14) 0.089
Height (cm) 177 (8) 168 (9) ,0.001
Weight (kg) 82 (13) 78 (15) ,0.001
BMI (kg/m
2) 26 (3) 27 (5) 0.001
Sugar intake (g/day) 49 (39) 46 (40) 0.095
Ethanol Intake (g/day) 30 (16) 1 (0.4)
Gender Male 252 (89%) 96 (32%) ,0.001
Female 31 (11%) 200 (68%)
Smoking Yes 193 (69%) 145 (49%) ,0.001
Data are presented as mean (SD) or as absolute numbers (%) for study variable;
p-values are calculated using Mann Whitney U test for continuous, and Chi
2 test
for categorical study variables respectively.
doi:10.1371/journal.pone.0018170.t001
Ghrelin and Sucrose Intake
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e18170plexiglass cages and were maintained at 20uC with 50% humidity.
Animals in the two-bottle choice experiments were maintained on
a 12 hour reversed light dark cycle (lights off at 10 am) and Long-
Evans rats in the operant self-administration experiments were
maintained on a regular 12 hour light-dark cycle (lights on at 7
a.m.). Food and water were available ad libitum, except for short
periods during initial training in the operant self-administration
paradigm, as described below. In all experiments the weight of
each animal was measured daily prior to bottle presentation, for
calculating the grams of saccharin/sucrose intake per kilogram of
body weight (g/kg). All experiments were performed in adult post-
pubertal age-matched male rats or mice.
Drugs
For mice, the selected dose of JMV2959, 6 mg/kg (i.p.),
(synthesized at the Institute des Biomole ´cules Max Mousseron
(IBMM), UMR5247, CNRS, Montpellier 1 and 2 Universities,
France), a GHS-R1A antagonist, was determined previously [5].
In the saccharin intake and taste aversion experiments this dose
did not affect the gross behavior of the mice. For Long-Evans rats
the selected doses were 1, 2 and 3 mg/kg JMV2959 since these
doses have been found to reduce alcohol intake and operant self-
administration in Long-Evans rats [34]. JMV2959 was always
administered 20 minutes prior to sucrose/saccharin exposure. It
has in previous studies been established as a GHS-R1A antagonist
[35]. JMV2959 was dissolved in vehicle (0.9% sodium chloride). A
balanced design was used in all drug challenges. The peripheral
(i.p.) administration of JMV2959 allowed studying repeated effects
over several days. Acylated rat ghrelin (Bionuclear; Bromma,
Sweden) was diluted in 0.9% sodium chloride (saline vehicle) and
was administrated peripehrally (i.p.) (1 ml/kg body weight). The
selected dose, 0.33 mg/kg, was determined previously, as it
increases locomotor activity and accumbal dopamine release as
well as induces a conditioned place preference in mice [36] and to
increase the motivation to consume sucrose in rats [37]. Ghrelin
was administered 10 min prior to the initiation of the experiments,
i.e. when light was turned out and the sucrose bottle was
presented. Lithium chloride (LiCl) (Sigma Ultra, Sigma Chemicals
CO; Stockholm, Sweden) was diluted in vehicle (0.9% sodium
chloride) and was administered at a dose previously reported to
produce aversion (150 mg/kg, i.p.). No gross behavioral effects of
LiCl were observed in these experiments. For all experiments
0.9% sodium chloride was used as vehicle.
Intermittent Access 5% Sucrose Two-bottle-choice
Drinking Paradigm
The intermittent access 5% sucrose two-bottle-choice drinking
paradigm is very similar to the intermittent access paradigm for
alcohol [31]. In brief, rats (n=12) were given access to one bottle
of 5% sucrose and one bottle of water for three 24-hour-sessions
per week (Mondays, Wednesdays and Fridays), 15 minutes after
the lights went out in a reversed light/dark cycle room. The rats
had unlimited access to two bottles of water between the sucrose-
access-periods. Bottles were weighed at 30 minutes, 6 hours and
24 hours after the fluids were presented and measurements were
taken to the nearest 0.1 gram. The weight of each animal was
measured daily prior to bottle presentation, for calculating the
grams of sucrose intake per kilogram of body weight (g/kg). The
preference for sucrose over water (the ratio of sucrose to total fluid
intake) was calculated at all time points. Drug administration
began once the animals had attained stable drinking levels of
sucrose about 7 weeks (approximately 20 drinking sessions).
JMV2959 (1, 2, and 3 mg/kg) or vehicle (saline) were adminis-
tered 20 minutes before the presentation of the sucrose bottles.
Each injection was given 7 days apart using a Latin square design,
thus each animal served as its own control. Between the injection
days, the rats were exposed to their normal drinking schedule of
intermittent access as described above with no injections for the
remaining days of that week. Sucrose was diluted in tap water to a
final concentration of 5% (w/v). The data were analyzed by
repeated-measures ANOVA, followed by a Newman–Keuls post
hoc analysis.
Operant Sucrose Self-Administration
Apparatus. Testing was conducted in standard operant
conditioning chambers (Coulbourn Instruments, Allentown, PA)
enclosed in ventilated, sound-attenuating cubicles. Each chamber
housed two retractable levers on the right wall with a liquid dipper
system placed centrally between them. A house light was present
on the wall opposite the levers and remained on at all times during
the operant session. Stimulus lights were present above each lever.
An apparatus to emit a tone under specific operant conditions was
also present. Upon correct (active) lever press(es), the stimulus light
above the active (right) lever was illuminated for 3 s and was
accompanied by a 3-s tone to reinforce availability of reward in the
dipper receptacle. The dipper port was illuminated for 10 s while
the dipper cup was available. Stimulus, fluid delivery, and operant
responses were all controlled and recorded by a computer
(Coulbourn Instruments) by using Graphic State 2.0 software.
Operant sucrose self-administration paradigm. Self-
administration testing was conducted in standard operant
conditioning chambers (Coulbourn Instruments, Allentown, PA)
as described previously [32,33]. In brief, rats (n=15) and trained
to self-administer 5% sucrose, on a fixed ratio 3 (FR3; three active
lever presses required for 0.1 ml reward) schedule of
reinforcement, daily (Monday through Friday) for 30 minutes.
Rats were kept on the FR3 protocol for at least 20 sessions before
treatment. To evaluate the acute effect of JMV2959 on sucrose
self-administration, JMV2959 (1, 2, and 3 mg/kg) or vehicle
(saline) were administered 20 minutes before the operant session.
Each injection was given 7 days apart in a Latin square design,
thus each animal served as its own control. Between the injection
days, the rats were exposed to their normal schedule of
reinforcement as described above with no injections for the
remaining days of that week. Additionally, food intake was
measured in the 24 hour period following the drug challenge in
order to further examine the non-specific appetitive effects of
JMV2959. The data were analyzed by repeated-measures
ANOVA, followed by a Newman–Keuls post hoc analysis.
Saccharin consumption paradigm
After one week of habituation the mice were housed individually
with continuous access to tap water and saccharin solution (0.1%)
for four weeks. Thereafter, the saccharin solution was limited to
the first three hours of the dark period and this limited access
paradigm was maintained for three weeks prior to GHS-R1A
antagonist treatment. Food and water was freely supplied during
the entire day. JMV2959 or vehicle was administered for two
subsequent days, due to advantages with peripheral administra-
tions. Thereafter, the mice were untreated for two days and the
saccharin intake was measured these days as well. These data were
analyzed as the average three hour intake over the two treatment
days. In all experiments the intake of saccharin and water were
measured throughout the three hour drinking session. The
24 hour food intake was also measured. The measurements of
saccharin consumption are expressed per gram body weight. The
effects of GHS-R1A treatment on intake in mice were evaluated
by a two-way ANOVA followed by Bonferroni post hoc test.
Ghrelin and Sucrose Intake
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Food and water were available ad libitum during the taste
aversion experiments. Saccharin solution (0.1%) was presented the
first three hours of the dark period and this procedure was
repeated every other day for a total of three saccharin drinking
days (Monday, Wednesday and Friday). At the end of the three
hours of saccharin consumption JMV2959, LiCl or vehicle was
administered. The first day (Monday) is considered as baseline
since the drugs were administered after saccharin consumption.
No saccharin or drug was presented the days in between treatment
(Tuesdays, Thursday and Saturday). The last day (Sunday)
saccharin was presented but no drug was administered. The
effects of GHS-R1A treatment on intake in mice were evaluated
by a two-way ANOVA followed by Bonferroni post hoc test.
However, the intake at baseline and after treatment was analyzed
with a one-way ANOVA followed by Bonferroni post hoc test.
Sucrose Consumption Paradigm
The 5% sucrose two-bottle-choice drinking paradigm is adapted
from a previous sucrose consumption paradigm [38]. In brief, rats
(n=16) were given access to one bottle of 5% sucrose and one
bottle of water for three hours for three subsequent days (Monday,
Tuesday, Wednesday) and a baseline intake of fluids and food was
established. The following week the rats had access to sucrose
bottle and were subjected to peripheral drug administration of
either ghrelin (0.33 mg/kg) or vehicle Monday and Wednesday.
The rats either received ghrelin (0.33 mg/kg) or vehicle day one
and vice versa treatment day two, thus each animal served as its
own control. The rats had unlimited access to two bottles of water
between the sucrose-access-periods. Bottles were weighed three
hours after the fluids were presented and measurements were
taken to the nearest 0.1 gram. The weight of each animal was
measured daily prior to bottle presentation, for calculating the
grams of sucrose intake per kilogram of body weight (g/kg). The
preference for sucrose over water (the ratio of sucrose to total fluid
intake) was calculated. The rat had free access to food before and
during the experiment and the food intake was measured during
the three hours of sucrose consumption. Sucrose was diluted in tap
water to a final concentration of 5% (w/v). The data were
analyzed by a paired t-test analysis.
Results
Genetics of the ghrelin signalling system and sucrose
intake in a population cohort
None of the SNPs differed significantly from HWE. SNP and
haplotype frequencies were similar to those previously reported
[26,27] and did not differ significantly between high- and low
alcohol consumers (data not shown).
When analyzing sucrose intake and the above mentioned
genetic markers in GHRL and GHSR in the population cohort,
associations with haplotypes (AGACGT and GACGT) in the
GHRL and increased sucrose consumption were found (Table 2),
i.e. carriers of these haplotypes have an increased sucrose
consumption compared to non-carriers. More specifically, the
haplotype GACGT was associated with increased sucrose intake
when analyzing all individuals (p=0.037) and high alcohol
consumers only (p=0.047) while a trend for the same association
was found in high consuming males (p=0.065). However, these
association did not hold for multiple testing (pc=0.074, pc=0.090
and pc=0.125, respectively). The nearly identical haplotype,
except for an additional SNP in the beginning, AGACGT was
associated with sucrose intake in all males (pc=0.045). Although
these association are quite modest, the largest representing a mere
20 g sucrose/day per allele which corresponds roughly to 7 pieces
of sugar or about one can of soda, they still implicate a relationship
between GHRL genetics, sucrose and alcohol consumption,
specifically in males.
The GHS-R1A antagonist decreases the sucrose intake in
the intermittent access 5% sucrose two-bottle-choice
drinking paradigm
We examined the effect of JMV2959 on voluntary sucrose
consumption in heavy drinking rats. Once the rats had
maintained stable baseline sucrose consumption for 7 weeks
(,20 sessions), JMV2959 (1, 2, and 3 mg/kg, i.p.) was
administered 20 min before the presentation of the sucrose
bottles. We found that JMV2959 treatment had an overall main
effect on sucrose consumption (g/kg) at the 30 min time point
[30 min: F(3,11)=15.03, P,0.0001, n=12], but showed no
effect at the 6 hr and 24 hr time points [6 hr: F(3,11)=1.10, n.s;
24 hr: F(3,11)=1.06, n.s]. Post hoc analysis revealed a
significant effect of JMV2959 (2 and 3 mg/kg) at the 30 min
time point (Figure 1A). There was also an overall main effect of
JMV2959 on the preference for sucrose over water at the 30 min
time point [30 min: F(3,11)=4.11, P,0.05](data not shown), but
showed no effect at the 6 hr and 24 hr time points [6 hr:
F(3,11)=0.54, n.s ; 24 hr: F(3,11)=0.69, n.s](data not shown).
JMV2959 had no overall main effect on water consumption at
any of the time points in the sucrose consuming rats [30 min:
F(3,11)=0.74, n.s; 6 hr: F(3,11)=0.12, n.s ; 24 hr: F(3,11)=
0.94, n.s](data not shown). JMV2959 treatment had no overall
main effect on body weight [F(3, 11)=1.29, n.s.](data not
shown).
Table 2. Haplotypes of the GHRL are associated with high sucrose intake.
Gene SNPs Haplo-type Group n=
Effect in
g/allele (±SE) p-value pc-value
GHRL 2–6 -GACGT High and Low EtOH 571 7 (64) 0.037 0.074
2–6 -GACGT High EtOH 279 10 (65) 0.047 0.090
1–6 AGACGT High and Low EtOH males 344 20 (610) 0.044 0.045
2–6 -GACGT High EtOH males 248 10 (66) 0.065 0.125
SNPs=single nucleotide polymorphism; GHRL=pro-ghrelin gene; SE=standard error; pc-values are calculated using regression models including associated haplotypes and
relevant covariates and are presented as values corrected for multiple testing by permutation analysis; p-values are based on likelihood ratios test while the 95% CIs are
calculated using Wald statistics.
doi:10.1371/journal.pone.0018170.t002
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in the operant self-administration procedures
We examined the effect of JMV2959 on sucrose self-
administration in Long-Evans rats. JMV2959 (1, 2, and 3 mg/
kg, i.p.) was administered 20 min before the operant session, once
the rats had maintained a stable level of responding for 5 weeks
(,25 FR3 sessions). JMV2959 treatment had an overall main
effect on 5% sucrose self-administration [F(3,14)=10.00, n=15]
(Figure 1B). Post hoc analysis revealed that both the 2 and 3 mg/
kg doses of JMV2959 (mg/kg) significantly decreased the number
of presses on the active lever compared to vehicle (Figure 1C).
Furthermore, JMV2959 had no overall main effect on the number
of presses on the inactive lever (Figure 1D) [F(3,14)=2.81, n.s].
There was no significant effect of JMV2959 treatment on food
intake in the sucrose trained animals [F(3,14)=1.42, n.s](data not
shown). JMV2959 treatment had no overall main effect on body
weight [F(3,14)=2.75, n.s](data not shown).
The GHS-R1A antagonist decreases the saccharin intake
in the saccharin consumption paradigm
In mice, we examined the effect of JMV2959 on voluntary
saccharin consumption. Mice were trained to consume saccharin
and established stable baseline consumption. At baseline, there
was no difference in saccharin intake between mice later subjected
to different treatments (vehicle 0.0460.002 g/kg/3 hrs; JMV2959
0.0560.002 g/kg/3 hrs) [F(1,23)=0.023, p=0.881]. In addition,
no difference in water intake was observed (vehicle 0.2460.01 g/
3 hrs; JMV2959 0.3060.20 g/3 hrs) [F(1,23)=1.63, p=0.213] or
24 hour food intake (vehicle 0.7660.03 g; JMV2959 0.7660.04 g
[F(1,23)=0.006, p=0.939] at baseline (data not shown). There-
after, JMV2959 (6 mg/kg, i.p.) or vehicle was administered
20 min before the presentation of the saccharin bottle.
JMV2959 or vehicle was administered for two subsequent days,
and as no difference in saccharin intake or preference was
observed between the two treatment days, the graph only shows
the average intake. We found that JMV2959 treatment had an
overall main effect on saccharin consumption (g/kg)
[F(1,23)=6.52, p=0.018; n=12 for JMV2959 and n=13 for
vehicle treatment] (Figure 2A) as well as on saccharin preference
(%) [F(1,23)=8.67, p=0.007] (Figure 2B). No effect on water
intake (g) was observed following JMV2959 treatment
[F(1,23)=1.32, p=0.261](data not shown). Additionally, we found
that JMV2959 treatment decreased the 90 min food consumption
(g) [F(1,23)=7.57, p=0.011] (Figure 2C), but not the 24 hour
Figure 1. The GHS-R1A antagonist reduces voluntary sucrose- intake and operant self-administration in rats. (A) JMV2959 treatment (2
and 3 mg/kg) decreased the sucrose consumption (g/kg) in the intermittent access 5% sucrose two-bottle-choice drinking paradigm. (B) GHS-R1A
antagonist treatment (2 and 3 mg/kg) reduced the consumption of 5% sucrose (g/kg) in the operant self-administration chamber, (C) JMV2959 (2 and 3 mg/
kg) significantly decreased the number of presses on the active lever compared to vehicle, (D) but did not affect the number of presses on the inactive lever.
doi:10.1371/journal.pone.0018170.g001
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treatment the mice were untreated for two days and there was no
difference in saccharin intake between mice subjected to different
treatments (vehicle 0.0560.005 g/kg/3 hrs; JMV2959 0.056
0.003 g/kg/3 hrs) [F(1,23)=0.533, p=0.473]. In addition, no
difference in water intake was observed (vehicle 0.3060.02 g/
90 min; JMV2959 0.3260.02 g/90 min) [F(1,23)=0.528, p=
0.476] or 24 hour food intake (vehicle 0.8160.07 g; JMV2959
1.0060.07 g) [F(1,23)=2.413, p=0.134] after treatment (data not
shown).
The GHS-R1A antagonist does not affect saccharin
consumption in the taste aversion set-up
The effects of JMV2959 or LiCl on voluntary saccharin
consumption in a taste aversion experiment in mice were studied.
At baseline, i.e. the first saccharin consumption day where mice
were treated after saccharin exposure, no differences in saccharin
intake [F(2,12)=0.827, p=0.461, n=5], saccharin preference
(F(2,12)=0.633, p=0.548), water intake [F(2,12)=0.395, p=
0.682] (Figure 3) or food intake [F(2,12)=0.907, p=0.430](data
not shown) were observed.
We found that treatment had an overall main effect on
saccharin consumption (g/kg) [F(2,12)=16.865, p=0.003, n=5]
as well as on saccharin preference (%) [F(2,12)=34.92, p,0.001].
Post hoc test showed that this was due to that LiCl reduced the
saccharin intake as well as preference each day compared to both
vehicle (p=0.0001; p,0.0001 respectively) and JMV2959
(p=0.0021; p,0.0001 respectively). There was no difference in
saccharin intake or preference between vehicle and JMV2959
(p=0.102; p=0.164 respectively). Moreover, treatment had an
overall main effect on water consumption (g) [F(2,12)=18.21,
p=0.002] (Figure 3). Post hoc test showed that this was due to a
compensatory increase in water intake after LiCl treatment
compared to both vehicle (p=0.0001) and JMV2959 (p=
0.0005) treatment. There was no difference in water intake
between vehicle and JMV2959 (p=0.372) treatment. Moreover,
treatment had no overall main effect on food consumption (g)
[F(2,12)=2.61, p=0.115](data not shown).
Figure 2. The GHS-R1A antagonist decreases saccharin intake in mice. (A) The GHS-R1A antagonist (6 mg/kg) decreased the saccharin
intake (g/kg) during the three hour limited access paradigm in mice compared to vehicle treatment. (B) JMV2959 (6 mg/kg) decreased the saccharin
preference over water (%). (C) The food intake (g) over the three hour period was decreased compared to vehicle treatment.
doi:10.1371/journal.pone.0018170.g002
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overall main effect of previous treatment on saccharin consump-
tion (g/kg) [F(2,12)=15.092, p=0.0005] as well as on saccharin
preference (%) [F(2,12)=34.92, p,0.001]. Post hoc test showed
that this was due to the previous LiCl treatment, which reduced
the saccharin intake as well as preference compared to previous
vehicle (p=0.0001; p,0.0001 respectively) and JMV2959
(p=0.0072; p,0.0001 respectively) treatment (Figure 3). There
was no difference in saccharin intake or preference between
previous vehicle and JMV2959 (p=0.0451; p=0.124 respectively)
treatment. Moreover, previous treatment had an overall main
effect on water consumption (g) [F(2,12)=20.201, p=0.002](data
not shown). Post hoc test showed that this was due to a
compensatory increase in water intake after previous LiCl
treatment compared to both vehicle (p=0.0001) and JMV2959
(p=0.0002) treatment. There was no difference in water intake
between previous vehicle and JMV2959 (p=0.850) treatment.
Moreover, previous treatment had no overall main effect on food
consumption (g) [F(2,12)=2.14, p=0.161](data not shown).
Ghrelin increases the sucrose intake in the sucrose
consumption paradigm
In rats, we examined the effect of peripheral administration of
ghrelin on voluntary sucrose consumption. Rats were trained to
consume sucrose and established stable baseline consumption
(sucrose intake 0.1160.01 g/kg/ 3 hrs; sucrose preference
96.5060.51%; water intake 0.8660.08 g/3 hrs; total fluid intake
28.0161.98 g/3 hrs; food intake 4.9160.26 g/3 hrs). Thereafter,
ghrelin (0.33 mg/kg, i.p.) or vehicle was administered 10 min
before the presentation of the sucrose bottle. We found that
ghrelin treatment increased the sucrose consumption in rats (g/kg)
(p=0.0273) (Figure 4A) as well as the food intake (p=0.0479)
(Figure 4B) in rats. No effect on sucrose preference (vehicle
94.4460.79%; ghrelin 94.8760.61%), water intake (vehicle
1.5660.28 g; ghrelin 1.4660.19 g) or total fluid intake (vehicle
28.3962.15 g; ghrelin 31.6663.24 g) was observed following
ghrelin treatment (p=0.663, p=0.786, 0.119 respectively).
Discussion
In the present study we found associations with the haplotype
AGACGT, and its shorter version, GACGT, in the GHRL and
increased sucrose consumption. The haplotype GACGT was
associated with increased sucrose intake in all individuals included
in the study, and a trend for the same association was specifically
seen in the high alcohol consumers. The nearly identical
haplotype, AGACGT, in the GHRL was associated with high
sucrose intake in male subjects. The preclinical data show that the
GHS-R1A antagonist reduces the intake of sucrose as well as
saccharin in rodents, as well as decreases self-administration of
sucrose in rats. Moreover, we found that the GHS-R1A antagonist
did not induce a taste aversion. Finally, the present study shows
that peripheral ghrelin administration increases the intake of
Figure 3. The GHS-R1A antagonist does not induce a taste
aversion in mice. The GHS-R1A antagonist (6 mg/kg) did not
affect the preference for saccharin over water compared to vehicle
treatment in the taste aversion experiment. LiCl, on the other hand,
decreased the preference for saccharin over water compared to both
JMV2959 and vehicle treatment (Square = vehicle; triangle = JMV2959;
Circle = LiCl).
doi:10.1371/journal.pone.0018170.g003
Figure 4. Peripheral ghrelin administration increases the sucrose intake in rats. Peripheral ghrelin (0.33 mg/kg) administration compared
to vehicle treatment increases (A) the sucrose intake (g/kg) as well as (B) food intake (g) in the three hour 5% sucrose two-bottle-choice drinking
paradigm in rats.
doi:10.1371/journal.pone.0018170.g004
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signalling, including the GHS-R1A, is important for regulation
of the consumption of rewarding substances in general, and that
this is independent of both the caloric content and any aversive
effect.
In the genetic part of this study, an association between a GHRL
haplotype and higher sucrose intake, particularly in males, was
found. This is in line with previous studies where male gender
specifically predicts a high preference for sweets [14,39], and that
sweet preference is a highly genetically determined trait [15]. Even
though the effect size of this association was quite modest and the
functional significance of this haplotype is yet unknown, it may be
suggested that the associated ghrelin-encoding polymorphisms
might influence the ability of the ghrelin signalling system to
regulate the intake of rewarding substances. Supportively, in the
preclinical experiments, we showed that pharmacological suppres-
sion of the GHS-R1A reduced high sucrose consumption as well as
operant self-administration of sucrose in rats. Further, peripheral
administration of ghrelin increased the intake and preference of
sucrose in rats. Supportively, it was recently shown that ghrelin
(administered centrally as well as peripherally) increases whereas
GHS-R1A antagonism suppresses the motivation to consume
sucrose [37] and that central grelin administration increase the
intake of sucrose in rats [38]. Given that the orexigenic peptide,
ghrelin, regulates energy balance [8], the reduced sucrose intake
may be related to its caloric content. However, this appears less
likely since we here show that GHS-R1A antagonism decreases
consumption of saccharin, a non-caloric sweetener, in mice.
Recently, peripheral ghrelin administration was shown to increase
the consumption of saccharin in wild type but not GHS-R1A
knockout mice [40]. Finally, we found that JMV2959 did not
induce a taste aversion in mice, as LiCl does, suggesting that the
reduced intake of sweet substances is due to suppressed reward
mechanisms rather than aversion.
A trend for an association between the GHRL haplotype,
AGACGT, and higher sucrose intake was also seen specifically
for the group with higher alcohol consumption. As this study
investigated a sample of individuals from a population cohort,
this trend needs to be further investigated in an alcohol
dependent population with a higher alcohol intake and possible
co-morbid eating disorder. These data are, however, of interest
since previously published studies show a positive correlation
with the response to sweet taste and excessive alcohol intake in
humans [18,41], and that SNPs and haplotypes of both the
GHRL and GHSR have been associated with increased weight
in alcohol dependent individuals [26]. Moreover, animals bred
for high saccharin preference show increased alcohol consump-
tion compared to low saccharin-preferring animals [42]. Given
that human imaging studies also reveal an underlying
disruption in the reward systems in addictive behaviors,
including alcohol use disorder and binge eating [1,2,3], we
suggest that underlying neurobiological mechanisms for such
addictive behaviors include central ghrelin signalling at the
level of the reward systems, such as the cholinergic-dopami-
nergic reward link [43].
From both preclinical and clinical data it now seems clear that
central ghrelin signalling, including both the peptide ghrelin and
its receptor, have a role in reward regulation. Indeed, here we
showed that ghrelin increases whereas GHS-R1A antagonist
reduced the intake and self-administration of sucrose in fed rats.
Additionally, recent studies show that ghrelin increases the intake
of sucrose in rats fed ad libitum as well as in rats subjected to mild
food restriction [37,38]. Furthermore, cocaine-seeking is associat-
ed with elevated plasma levels of ghrelin and a peripheral ghrelin
injection enhances cocaine-induced locomotor stimulation and
conditioned place preference [44,45,46]. Moreover, ghrelin
administration in to the brain ventricles or into the VTA or
LDTg, important reward nodes, increases alcohol consumption in
mice [5] and the alcohol-induced locomotor stimulation and
accumbal dopamine releases is attenuated in ghrelin knockout
mice [4]. Further, ghrelin increases foraging in rats [47] and
enhances the activity of reward-related brain nodes in humans
subjected to food-related cues [48]. In human genetic studies a
GHRL haplotype has been associated with paternal heredity of
alcohol-use disorder [27], of increased weight in alcohol
dependent individuals [26], as well as with increased sucrose
consumption, as shown in the present study. Regarding the GHS-
R1A, it was recently shown that GHS-R1A suppression reduces
the intake of as well as the motivation to obtain palatable food [6]
and attenuates alcohol-, cocaine-, and amphetamine-induced
reward, as measured by locomotor activity, accumbal dopamine
release and conditioned place preference [5,13]. Further central or
peripheral administration of a GHS-R1A antagonist reduces
alcohol consumption as well as self-administration of alcohol in
both mice and rats [5,34,49]. Supportively, present and recent
studies have shown that GHS-R1A antagonism decreases the
intake of sweet substances in rodents [37,40]. Associations with
one SNP and of haplotypes in GHSR and alcohol consumption,
increased weight in alcohol dependent individuals, as well as with
smoking in female alcohol dependence have been shown [26,27].
Conclusively, these clinical and preclinical findings suggest that
ghrelin signalling may regulate both the intake of and search for
rewarding substances, and a possible role for ghrelin signalling in
patients with multiple addictions.
It now seems clear that ghrelin activates the cholinergic-
dopaminergic reward link and that ghrelin thereby increase the
incentive value for motivated behaviors i.e. reward-seeking [9,10].
Given that the present and recent studies show that ghrelin
increase and that the GHS-R1A antagonist reduces the intake of
sucrose in rats [37,38], it should be considered that the role of
ghrelin signaling for the consumption of sweets is related to the
endogenous peptide ghrelin and/or to the GHS-R1A. However,
the specific mechanisms through which ghrelin signalling may
regulate the intake of rewarding substances need to be further
elucidated. One possibility is that ghrelin amplifies dopamine
signalling in the mesolimbic dopamine system through cross-talk
involving heterodimerization of GHS-R1A and dopamine D1-like
receptors, receptors co-localized on dopaminergic neurons in the
VTA [50]. Another possibility is that the GHS-R1A via its
constitutive activity regulates the sensitivity of the mesolimbic
dopamine system, and the ability of drugs of abuse to activate this
system [51].
Here, we showed that haplotypes in the GHRL are associated
with increased sucrose consumption in humans. We also showed
that a GHS-R1A antagonist reduces the consumption of both
sucrose and saccharin, as well as the self-administration of sucrose
in rodents. Collectively, our data provide a clear indication that
the central ghrelin signalling system, via GHS-R1A, is involved in
regulating the intake of rewarding substance and hence, provides a
novel target for the development of drug strategies to treat
addictive behaviors.
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